ClinVar Miner

Submissions for variant NM_031885.5(BBS2):c.661del (p.Leu221fs)

dbSNP: rs770258677
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 9
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine RCV000190568 SCV000245581 pathogenic Bardet-Biedl syndrome 2 2015-01-20 criteria provided, single submitter clinical testing The p.Leu221PhefsX25 variant in BBS2 has been reported in 1 homozygous and 2 compound heterozygous individuals with Bardet-Biedl syndrome (BBS; Hjortshøj 2010). This variant has been identified in 0.03% (2/6592) of European (Finnish) chromosomes by the Exome Aggregation Consortium (ExAC, Although this variant has been seen in the general population, its frequency is low enough to be consistent with a recessive carrier frequency. This variant is predicted to cause a frameshift, which alters the protein’s amino acid sequence beginning at position 221 and leads to a premature termination codon 25 amino acids downstream. This alteration is then predicted to lead to a truncated or absent protein. Complete loss of BBS2 function is an established disease mechanism in BBS. In summary, this variant meets our criteria to be classified as pathogenic for BBS in an autosomal recessive manner.
Counsyl RCV000190568 SCV000790211 likely pathogenic Bardet-Biedl syndrome 2 2017-03-15 criteria provided, single submitter clinical testing
Invitae RCV001248493 SCV001421982 pathogenic Bardet-Biedl syndrome 2024-01-03 criteria provided, single submitter clinical testing This sequence change creates a premature translational stop signal (p.Leu221Phefs*25) in the BBS2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in BBS2 are known to be pathogenic (PMID: 11285252, 20177705, 24608809, 26518167). This variant is present in population databases (rs770258677, gnomAD 0.02%). This premature translational stop signal has been observed in individuals with Bardet-Biedl syndrome (PMID: 20120035). ClinVar contains an entry for this variant (Variation ID: 208564). For these reasons, this variant has been classified as Pathogenic.
Institute of Medical Genetics and Applied Genomics, University Hospital Tübingen RCV001268712 SCV001447841 pathogenic not provided 2020-10-23 criteria provided, single submitter clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV001248493 SCV002555692 pathogenic Bardet-Biedl syndrome 2022-06-06 criteria provided, single submitter clinical testing Variant summary: BBS2 c.661delC (p.Leu221PhefsX25) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory. The variant allele was found at a frequency of 2e-05 in 251270 control chromosomes (gnomAD). c.661delC has been reported in the literature in both homozygous and compound heterozygous individuals affected with Bardet-Biedl Syndrome (Hjortshoj_2010). These data indicate that the variant is likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Six ClinVar submitters have assessed the variant since 2014: one classified the variant as likely pathogenic and five classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.
Ambry Genetics RCV002517028 SCV003651427 pathogenic Inborn genetic diseases 2021-02-23 criteria provided, single submitter clinical testing The c.661delC (p.L221Ffs*25) alteration, located in exon 6 (coding exon 6) of the BBS2 gene, consists of a deletion of one nucleotide at position 661, causing a translational frameshift with a predicted alternate stop codon after 25 amino acids. This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. Based on data from gnomAD, the BBS2 c.661delC alteration has an overall frequency of <0.01% (7/282674) total alleles studied. The highest observed frequency was 0.02% (5/25080) of European (Finnish) alleles. This pathogenic alteration has been reported in multiple unrelated individuals with Bardet-Biedl syndrome (BBS) in the homozygous state or in conjunction with a second pathogenic BBS2 allele (Hjortsh&oslash;j, 2010). Based on the available evidence, this alteration is classified as pathogenic.
Baylor Genetics RCV000190568 SCV004214034 pathogenic Bardet-Biedl syndrome 2 2023-04-24 criteria provided, single submitter clinical testing
Department of Clinical Genetics, Copenhagen University Hospital, Rigshospitalet RCV000787790 SCV000926800 pathogenic Retinitis pigmentosa 2018-04-01 no assertion criteria provided research
Natera, Inc. RCV000190568 SCV001457443 pathogenic Bardet-Biedl syndrome 2 2020-09-16 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.